A Look at ACC’s Scientific Statement on Inflammation and CVD
In this week’s View, Dr. Eagle looks at an ACC Scientific Statement highlighting inflammation and its role in cardiovascular disease (CVD). He then explores left atrial appendage occlusion (LAAO) in patients with prior intracranial hemorrhage or ischemic stroke. Finally, Dr. Eagle discusses the recently released NEWTON-CABG CardioLink-5 trial on the use of evolocumab in the reduction of saphenous vein graft (SVG) disease rates. Subscribe to Eagle’s Eye View
--------
7:07
--------
7:07
Oral Semaglutide for Weight Loss; Anticoagulants for PAH; The ECDP on TR Evaluation and Management
In this week’s View, Dr. Eagle looks at the value of oral semaglutide for weight loss. He then explores whether anticoagulants improve survival in patients with pulmonary arterial hypertension (PAH). Finally, Dr. Eagle discusses the recent release of the ACC Expert Consensus Decision Pathway (ECDP) on tricuspid regurgitation (TR) evaluation and management. Subscribe to Eagle’s Eye View
--------
7:08
--------
7:08
Nonatherothrombotic Myocardial Infarction and SCAD in Younger Patients; the Benefit of Intensive Blood Pressure Control; Clopidogrel vs. Aspirin for Prevention of CV Events
In this week’s View, Dr. Eagle looks at the net benefit of intensive blood pressure control between fewer cardiovascular and more adverse events. He then explores non-atherothrombotic myocardial infarction events and spontaneous coronary artery dissection (SCAD) in younger patients – something more commonly found among young women than young men. Finally, Dr. Eagle discusses whether clopidogrel is superior to aspirin for the prevention of major adverse cardiovascular or cerebrovascular events in patients with coronary artery disease (CAD). Subscribe to Eagle’s Eye View
--------
6:59
--------
6:59
Aspirin in PCI; Mavacamten in Nonobstructive Cardiomyopathy; Olezarsen and the Treatment of Hypertriglyceridemia
Dr. Eagle continues in this week’s View to analyze some of the key clinical content presented at the ESC Congress recently held in Spain. Dr. Eagle examines the TARGET-FIRST trial in which P2Y12-inhibitor monotherapy was compared to dual antiplatelet therapy (DAPT) in patients who have undergone percutaneous coronary intervention (PCI). He then analyzes the results of the ODYSSEY-HCM trial which explored mavacamten versus placebo in patients with symptomatic nonobstructive hypertrophic cardiomyopathy (HCM). Finally, Dr. Eagle discusses the ESSENCE-TIMI 73b study that looked at olezarsen and its potential for lowering triglycerides in moderate hypertriglyceridemia with elevated cardiovascular risk. Subscribe to Eagle’s Eye View
--------
6:10
--------
6:10
Aficamten vs. Metoprolol for HCM; Beta Blocks and Myocardial Infarction (MI); Reconditioned Pacemakers for Improving Global CV Health
In this week’s View, Dr. Eagle looks at major trials presented at the recent ESC Congress in Spain. First, he discusses the MAPLE-HCM trial that investigates aficamten versus metoprolol monotherapy in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM). He then explores a set of important presentations on beta blocker therapy following myocardial infarction. Finally, Dr. Eagle talks about new research on the use of reconditioned pacemakers that shows promise for strengthening global cardiovascular health. Subscribe to Eagle’s Eye View
Acerca de Eagle's Eye View: Your Weekly CV Update From ACC.org
The weekly cardiovascular update from Kim Eagle, MD, MACC for ACC.org covering the hottest cardiovascular topics, from new clinical guidelines to practice-changing research and innovative quality initiatives and tools.
Colombia